We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-11.53%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$361M
AUM Growth
+$175M
Cap. Flow
-$29.7M
Cap. Flow %
-8.24%
Top 10 Hldgs %
90.77%
Holding
111
New
18
Increased
19
Reduced
27
Closed
38

Top Buys

Rank Stock Value
1
GLD icon
SPDR Gold Trust
GLD
+$5.25M
2
TRAW icon
Traws Pharma
TRAW
+$3.96M
3
NBRV
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
+$1.9M
4
BPTH
Bio-Path Holdings Inc
BPTH
+$1.16M
5
TOPS icon
TOP Ships
TOPS
+$1.13M

Top Sells

Rank Stock Value
1
TEUM
Pareteum Corporation
TEUM
+$2.9M
2
RDGT
Ridgetech Inc
RDGT
+$1.59M
3
CRMD icon
CorMedix
CRMD
+$1.59M
4
ARCT icon
Arcturus Therapeutics
ARCT
+$1.28M
5
ATNM icon
Actinium Pharmaceuticals
ATNM
+$1.27M

Sector Composition

Rank Sector Weight
1 Healthcare 5.35%
2 Industrials 0.18%
3 Technology 0.07%
4 Consumer Discretionary 0.01%
5 Materials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$783B
$177M 49.08%
5,500
+4,502
+451% +$1.39M
SPY icon
2
CALL
State Street SPDR S&P 500 ETF Trust
SPY
$783B
$52M 14.42%
1,616
+1,111
+220% +$342K
GLD icon
3
PUT
SPDR Gold Trust
GLD
$131B
$24.8M 6.89%
+1,738
New +$243K
OEF icon
4
CALL
iShares S&P 100 ETF
OEF
$19.8B
$21.5M 5.96%
1,298
-265
-17% -$36.4K
IONS icon
5
CALL
Ionis Pharmaceuticals
IONS
$9.14B
$17.9M 4.96%
2,961
-77
-3% -$4.59K
GLD icon
6
CALL
SPDR Gold Trust
GLD
$131B
$15.3M 4.24%
1,070
-1,358
-56% -$190K
GLD icon
7
SPDR Gold Trust
GLD
$131B
$5.37M 1.49%
+37,550
New +$5.25M
XNTK icon
8
PUT
State Street SPDR NYSE Technology ETF
XNTK
$2B
$4.76M 1.32%
500
-7
-1% -$536
AMRN
9
PUT
Amarin Corp
AMRN
$293M
$4.39M 1.22%
102
-13
-11% -$4.94K
AMRN
10
CALL
Amarin Corp
AMRN
$293M
$4.37M 1.21%
102
+6
+6% +$2.28K
XNTK icon
11
CALL
State Street SPDR NYSE Technology ETF
XNTK
$2B
$3.66M 1.02%
+385
New +$29.5K
TRAW icon
12
Traws Pharma
TRAW
$7.81M
$3.35M 0.93%
23,310
+21,169
+989% +$3.96M
ODT
13
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$1.75M 0.48%
53,839
-39,015
-42% -$1.21M
ARQL
14
CALL
DELISTED
Arqule Inc
ARQL
$1.54M 0.43%
+772
New +$8.95K
NBRV
15
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$1.37M 0.38%
+4,143
New +$1.9M
SRNE
16
PUT
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$1.17M 0.33%
+3,471
New +$8.28K
GNCA
17
DELISTED
Genocea Biosciences, Inc.
GNCA
$1.11M 0.31%
538,359
+61,008
+13% +$145K
HIND
18
Vyome Holdings
HIND
$14M
$1.08M 0.3%
1
– –
BPTH
19
DELISTED
Bio-Path Holdings Inc
BPTH
$986K 0.27%
+6,167
New +$1.16M
BCLI
20
PUT
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
$894K 0.25%
139
-35
-20% -$2.03K
PAVMZ
21
DELISTED
PAVmed Inc. Series Z Warrant
PAVMZ
$836K 0.23%
2,152,719
-811,910
-27% -$255K
BIIB icon
22
CALL
Biogen
BIIB
$30.4B
$831K 0.23%
+28
New +$7.77K
ORMP icon
23
PUT
Oramed Pharmaceuticals
ORMP
$171M
$804K 0.22%
1,562
+1,427
+1,057% +$5.35K
MBOT icon
24
Microbot Medical
MBOT
$113M
$773K 0.21%
76,000
-7,333
-9% -$43K
ATNM icon
25
Actinium Pharmaceuticals
ATNM
$27.2M
$713K 0.2%
109,191
-184,059
-63% -$1.27M
1
2 3 4 5

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q4 2019 Portfolio in Review

As of Q4 2019, Sabby Management held 111 positions worth $361M, up 94% from $186M the previous quarter. Its ten largest holdings account for 91% of the portfolio.

Sabby Management withdrew a net $29.7M in Q4 2019, closing 38 positions and reducing 27 holdings. Its most notable exit was Pareteum Corporation, an estimated $2.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 5.4% of assets, down from 15% a quarter earlier, followed by Industrials and Technology.

Against the trend, Sabby Management opened a new position in SPDR Gold Trust worth $5.37M.

  • Sabby Management's largest Q4 2019 buy was SPDR Gold Trust: 37,550 shares worth $5.37M.
  • Sabby Management added most to Traws Pharma in Q4 2019, an estimated $3.96M increase.
  • Sabby Management's biggest Q4 2019 reduction was Actinium Pharmaceuticals, cutting an estimated $1.27M.
  • Sabby Management fully exited Pareteum Corporation in Q4 2019, selling an estimated $2.9M.
  • Sabby Management's ten largest holdings make up 91% of its $361M portfolio in Q4 2019.
  • Sabby Management opened 18 new positions and closed 38 in Q4 2019.
  • Sabby Management's portfolio value rose 94% quarter-over-quarter to $361M.

Based on Sabby Management's 13F filing for Q4 2019, filed 14 Feb 2020.